Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy

Cancer

Volumn 78, Issue 10, 1996, Pages 2157-2163

  Recio, Fernando O ^a   Piyer, M Steven ^a   Hempling, Ronald E ^a   Driscoll, Deborah L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

clear cell ovarian carcinoma; platinum; survival; thromboembolic complications

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACTINOMYCIN; FLUOROURACIL; MELPHALAN; METHOTREXATE; PLATINUM;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; POSTOPERATIVE CARE; PRIORITY JOURNAL; THROMBOEMBOLISM;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOEMBOLISM;

EID: 0029981116     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961115)78:10<2157::AID-CNCR17>3.0.CO;2-Y     Document Type: Article

References (21)

1. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. BMJ 1991;303:884-93.
2. Jenison EL, Montag AG, Griffiths CT, Welch WR, Lavin PT, Greer J, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989;32:65-71.
3. Kennedy AW, Biscotti CV, Hart WR, Webster KH. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989:32:342-9.
4. O'Brien MER, Schofield JB, Tan S, Fryatt I, Fisher C, Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stage. Gynecol Oncol 1993; 49:250-4.
5. Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60:412-7.
6. Piver MS, Barlow JJ, Yazigi R, Blumenson LE. Melphalan chemotherapy in advanced ovarian carcinoma. Obstet Gynecol 1978;51:352-6.
7. Barlow JJ, Piver MS, Lele SB. High dose methotrexate with "rescue" plus cyclophosphamide as initial chemotherapy in ovarian adenocarcinoma. A randomized trial with observations on the influence of C. parvum immunotherapy. Cancer 1980;46:1333-8.
8. Barlow JJ, Piver MS. Single agent vs. combination chemotherapy in the treatment of ovarian cancer. Obstet Gynecol 1977;49:609-11.
9. Barlow JJ, Lele SB. Cisplatin-MECY (methotrexate, leucovorin rescue plus cyclophosphamide) vs cisplatin CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin and cisplatin) as initial therapy in Stage III and IV ovarian adenocarcinoma. Cancer Treat Rep 1984;68:1433-8.
10. Piver MS, Lele SB, Marchetti DL, Baker TR, Tsukada Y, Emrich LJ. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression free survival in Stage III and IV ovarian carcinoma. J Clin Oncol 1988;6:983-9.
11. Baker TR, Piver MS, Hempling RE. Long-term survival by cytoreductive surgery to < 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian adenocarcinoma. Cancer 1994; 74:656-6 3.
12. Piver MS, Malfetano J, Baker TR, Lele SB, Marchetti DL. Adjuvant cisplatin-based chemotherapy for Stage I ovarian adenocarcinoma (a preliminary report). Gynecol Oncol 1989; 35:69-72.
13. Piver MS, Malfetano J, Hempling RE, Baker TR, Driscoll DL. Cisplatin-based chemotherapy for Stage II ovarian adenocarcinoma: a preliminary report. Gynecol Oncol 1990; 39:249-52.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
15. Young RC, Walton LA, Ellenberg SS. Adjuvant therapy in Stage 1 and II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med 1990;322:1021-7.
16. Yoonessi M, Weldon D, Satchidand SK, Crickard K. Clear cell ovarian adenocarcinoma. J Surg Oncol 1984; 27:289-97.
17. Ansley JT, Blythe JG. Fibrin degradation products and the diagnosis of ovarian carcinoma. Obstet Gynecol 1978; 52:605-8.
18. Miller B, Heilmann L. Hemorheological parameters in patients with gynecologic malignancies. Gynecol Oncol 1989; 33:177-81.
19. Canney PA, Wilkinson PM. Pulmonary embolism in patients receiving chemotherapy for advanced ovarian cancer. Eur J Cancer Clin Oncol 1985;21:585-6.
20. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
21. Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium. A clinicopathologic study of clear cell carcinoma and secretory carcinoma. Cancer 1982; 49:1511-23.